Vertex reaches agreements with Denmark, Austria over access to CF drugs

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said it has entered into an contract with Amgros, Denmark's pharmaceutical procurement organization, for access to the biotech's cystic fibrosis portfolio. The agreement includes current and future CF drugs.

Vertex's approved drugs in the EU are Kalydeco ivacaftor and Orkambi ivacaftor/lumacaftor. In July, EMA's CHMP backed a third drug, Symkevi tezacaftor/ivacaftor...